The post MLB Sees Dramatic Drop In PED Suspensions appeared on BitcoinEthereumNews.com. Performance enhancing drugs in Major League Baseball was once a regular headline story, but over several years, there has been a significant decline in PED suspensions and players seeking therapeutic use exemptions. getty Once a burning issue for Major League Baseball, the number of suspensions for players using performance-enhancing drugs – as well as therapeutic use exemptions for banned substances – has dropped dramatically in recent years. An annual report for 2025 shows that trend continuing. If you don’t recall Alex Sanchez of the Tampa Bay Rays in 2005, you’d be forgiven. But Sanchez has a unique place in the history of Major League Baseball. On January 3, 2005, he became the first player in history suspended for a violation of MLB’s drug testing policy, serving a 10-game suspension. In the first year of the Major League Drug Prevention and Treatment Program, which was reached between MLB and the MLB Players Association, a total of 12 players were suspended for PEDs. It would not be until the Biogenesis scandal of 2013 that the likes of Alex Rodriguez, Nelson Cruz, Ryan Braun, Jhonny Peralta, and more would push MLB PED suspensions to a historical high of 16. The specter of performance-enhancing substances will never leave the sport, but in recent years, there has been a significant decline in not just suspensions, but also in the allowance of therapeutic use exemptions (TUEs) for the use of what would usually be banned substances. Each year, MLB and the MLBPA release an annual report on drug testing in the league. The report is issued by an Independent Program Administrator; this year, Thomas M. Martin, Ph.D. For 2025, the total number of drug tests that were conducted totaled 11,700. Of those, 9.400 were urine samples. The number of dried blood spot samples that were collected… The post MLB Sees Dramatic Drop In PED Suspensions appeared on BitcoinEthereumNews.com. Performance enhancing drugs in Major League Baseball was once a regular headline story, but over several years, there has been a significant decline in PED suspensions and players seeking therapeutic use exemptions. getty Once a burning issue for Major League Baseball, the number of suspensions for players using performance-enhancing drugs – as well as therapeutic use exemptions for banned substances – has dropped dramatically in recent years. An annual report for 2025 shows that trend continuing. If you don’t recall Alex Sanchez of the Tampa Bay Rays in 2005, you’d be forgiven. But Sanchez has a unique place in the history of Major League Baseball. On January 3, 2005, he became the first player in history suspended for a violation of MLB’s drug testing policy, serving a 10-game suspension. In the first year of the Major League Drug Prevention and Treatment Program, which was reached between MLB and the MLB Players Association, a total of 12 players were suspended for PEDs. It would not be until the Biogenesis scandal of 2013 that the likes of Alex Rodriguez, Nelson Cruz, Ryan Braun, Jhonny Peralta, and more would push MLB PED suspensions to a historical high of 16. The specter of performance-enhancing substances will never leave the sport, but in recent years, there has been a significant decline in not just suspensions, but also in the allowance of therapeutic use exemptions (TUEs) for the use of what would usually be banned substances. Each year, MLB and the MLBPA release an annual report on drug testing in the league. The report is issued by an Independent Program Administrator; this year, Thomas M. Martin, Ph.D. For 2025, the total number of drug tests that were conducted totaled 11,700. Of those, 9.400 were urine samples. The number of dried blood spot samples that were collected…

MLB Sees Dramatic Drop In PED Suspensions

2025/12/03 21:41

Performance enhancing drugs in Major League Baseball was once a regular headline story, but over several years, there has been a significant decline in PED suspensions and players seeking therapeutic use exemptions.

getty

Once a burning issue for Major League Baseball, the number of suspensions for players using performance-enhancing drugs – as well as therapeutic use exemptions for banned substances – has dropped dramatically in recent years. An annual report for 2025 shows that trend continuing.

If you don’t recall Alex Sanchez of the Tampa Bay Rays in 2005, you’d be forgiven. But Sanchez has a unique place in the history of Major League Baseball. On January 3, 2005, he became the first player in history suspended for a violation of MLB’s drug testing policy, serving a 10-game suspension. In the first year of the Major League Drug Prevention and Treatment Program, which was reached between MLB and the MLB Players Association, a total of 12 players were suspended for PEDs. It would not be until the Biogenesis scandal of 2013 that the likes of Alex Rodriguez, Nelson Cruz, Ryan Braun, Jhonny Peralta, and more would push MLB PED suspensions to a historical high of 16.

The specter of performance-enhancing substances will never leave the sport, but in recent years, there has been a significant decline in not just suspensions, but also in the allowance of therapeutic use exemptions (TUEs) for the use of what would usually be banned substances.

Each year, MLB and the MLBPA release an annual report on drug testing in the league. The report is issued by an Independent Program Administrator; this year, Thomas M. Martin, Ph.D.

For 2025, the total number of drug tests that were conducted totaled 11,700. Of those, 9.400 were urine samples. The number of dried blood spot samples that were collected and analyzed for the presence of human growth hormone (hGH) was 2,300.

Of those tests, two resulted in adverse findings that led to suspensions. In all cases, players are retested if there are adverse findings. Should the findings remain and fall under the substances that result in suspension, a player can appeal the suspension. Therefore, when a suspension is announced, it is a considerable period of time after the player tests positive for PEDs.

For 2025, there were two players suspended for violating the drug program:

On May 18th, José Alvarado received an 80-game suspension without pay after testing positive for exogenous Testosterone. On May 31st, Jurickson Profar received an 80-game suspension without pay after testing positive for Chorionic Gonadotrophin (hCG). In both cases, the suspensions were for performance-enhancing substances.

Therapeutic Use Exemptions For Otherwise Banned Substances

The league and MLBPA have allowed a system in which players, through a doctor’s care, and apply for what is called a Therapeutic Use Exemption, or TUEs. The TUEs is granted after comprehensive medical documentation to prove the medical need for the medication and demonstrate that the treatment only returns the athlete to a normal level of health, rather than providing an unfair advantage. In the vast majority of the TUEs granted each year, the exemption is made for Attention Deficit Hyperactivity Disorder (ADHD) medications. These medications are often amphetamine derivatives, and given that amphetamines are banned in MLB, the player would need an exemption to use such meds to address ADHD.

In years past, the number of ADHD TUEs has reached over 100, which raised the question as to whether there was a fundamental loophole in the drug testing program.

But over the years, these numbers have declined dramatically. For 2025, there was a total of 57 TUEs granted, with 54 for ADHD, along with one each granted for hypertension, sleep disorder, and hormone function. In all cases, the players granted TUEs are not released in the annual report. The drug testing program does not allow for therapeutic use exemptions for human growth hormone.

The 57 total therapeutic use exemptions in 2025 is a -37% drop from the 91 granted in 2020, and shows the drop over just the past six years. While there will likely never be a day when there are no suspensions and no therapeutic use exemptions, for now, at least within the drug program, Major League Baseball is about as free from PEDs as it may ever be.

The table below shows the number of PED suspensions, the total number of therapeutic use exemptions, and the number of those that are ADHD related from 2020 to 2025.

Graphical representation of MLB drug suspension, TUEs, and those that are for ADHD

Maury Brown

Source: https://www.forbes.com/sites/maurybrown/2025/12/03/mlb-sees-dramatic-drop-in-ped-suspensions/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Ripple Buyers Step In at $2.00 Floor on BTC’s Hover Above $91K

Ripple Buyers Step In at $2.00 Floor on BTC’s Hover Above $91K

The post Ripple Buyers Step In at $2.00 Floor on BTC’s Hover Above $91K appeared on BitcoinEthereumNews.com. Token breaks above key support while volume surges 251% during psychological level defense at $2.00. News Background U.S. spot XRP ETFs continue pulling in uninterrupted inflows, with cumulative demand now exceeding $1 billion since launch — the fastest early adoption pace for any altcoin ETF. Institutional participation remains strong even as retail sentiment remains muted, contributing to market conditions where large players accumulate during weakness while short-term traders hesitate to re-enter. XRP’s macro environment remains dominated by capital rotation into regulated products, with ETF demand offsetting declining open interest in derivatives markets. Technical Analysis The defining moment of the session came during the $2.03 → $2.00 flush when volume spiked to 129.7M — 251% above the 24-hour average. This confirmed heavy selling pressure but, more importantly, marked the exact moment where institutional buyers absorbed liquidity at the psychological floor. The V-shaped rebound from $2.00 back into the $2.07–$2.08 range validates active demand at this level. XRP continues to form a series of higher lows on intraday charts, signaling early trend reacceleration. However, failure to break through the $2.08–$2.11 resistance cluster shows lingering supply overhead as the market awaits a decisive catalyst. Momentum indicators show bullish divergence forming, but volume needs to expand during upside moves rather than only during downside flushes to confirm a sustainable breakout. Price Action Summary XRP traded between $2.00 and $2.08 across the 24-hour window, with a sharp selloff testing the psychological floor before immediate absorption. Three intraday advances toward $2.08 failed to clear resistance, keeping price capped despite improving structure. Consolidation near $2.06–$2.08 into the session close signals stabilization above support, though broader range compression persists. What Traders Should Know The $2.00 level remains the most important line in the sand — both technically and psychologically. Institutional accumulation beneath this threshold hints at larger players…
Share
BitcoinEthereumNews2025/12/08 13:22
China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise

China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise

The post China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise appeared on BitcoinEthereumNews.com. China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise China’s internet regulator has ordered the country’s biggest technology firms, including Alibaba and ByteDance, to stop purchasing Nvidia’s RTX Pro 6000D GPUs. According to the Financial Times, the move shuts down the last major channel for mass supplies of American chips to the Chinese market. Why Beijing Halted Nvidia Purchases Chinese companies had planned to buy tens of thousands of RTX Pro 6000D accelerators and had already begun testing them in servers. But regulators intervened, halting the purchases and signaling stricter controls than earlier measures placed on Nvidia’s H20 chip. Image: Nvidia An audit compared Huawei and Cambricon processors, along with chips developed by Alibaba and Baidu, against Nvidia’s export-approved products. Regulators concluded that Chinese chips had reached performance levels comparable to the restricted U.S. models. This assessment pushed authorities to advise firms to rely more heavily on domestic processors, further tightening Nvidia’s already limited position in China. China’s Drive Toward Tech Independence The decision highlights Beijing’s focus on import substitution — developing self-sufficient chip production to reduce reliance on U.S. supplies. “The signal is now clear: all attention is focused on building a domestic ecosystem,” said a representative of a leading Chinese tech company. Nvidia had unveiled the RTX Pro 6000D in July 2025 during CEO Jensen Huang’s visit to Beijing, in an attempt to keep a foothold in China after Washington restricted exports of its most advanced chips. But momentum is shifting. Industry sources told the Financial Times that Chinese manufacturers plan to triple AI chip production next year to meet growing demand. They believe “domestic supply will now be sufficient without Nvidia.” What It Means for the Future With Huawei, Cambricon, Alibaba, and Baidu stepping up, China is positioning itself for long-term technological independence. Nvidia, meanwhile, faces…
Share
BitcoinEthereumNews2025/09/18 01:37